These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 29496411)
1. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411 [TBL] [Abstract][Full Text] [Related]
2. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537 [TBL] [Abstract][Full Text] [Related]
3. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors. Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007 [TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†. Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors. Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192 [TBL] [Abstract][Full Text] [Related]
10. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors. Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421 [TBL] [Abstract][Full Text] [Related]
11. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors. Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies. El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase/phosphodiesterase inhibitors and antiproliferative agents. Ullah S; El-Gamal MI; El-Gamal R; Pelletier J; Sévigny J; Shehata MK; Anbar HS; Iqbal J Eur J Med Chem; 2021 May; 217():113339. PubMed ID: 33744686 [TBL] [Abstract][Full Text] [Related]
16. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. Zhang H; Wang J; Shen Y; Wang HY; Duan WM; Zhao HY; Hei YY; Xin M; Cao YX; Zhang SQ Eur J Med Chem; 2018 Mar; 148():221-237. PubMed ID: 29466773 [TBL] [Abstract][Full Text] [Related]
17. 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity. Naaz F; Preeti Pallavi MC; Shafi S; Mulakayala N; Shahar Yar M; Sampath Kumar HM Bioorg Chem; 2018 Dec; 81():1-20. PubMed ID: 30081353 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors. Mao Y; Zhu W; Kong X; Wang Z; Xie H; Ding J; Terrett NK; Shen J; Shen J Bioorg Med Chem; 2013 Jun; 21(11):3090-104. PubMed ID: 23602524 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]